Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing

MedPage Today) -- SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of plasma concentrations compared with twice-yearly subcutaneous lenacapavir for HIV pre...

Market Touch Signal is a free discovery window from Oy Market Touch Ltd. Practical intelligence, clear communication and useful digital ventures: https://market-touch.org/
Get In Touch

Market Touch Signal · Finland · international digital desk

+358 400 512311

info@market-touch.org

Follow Us
Flickr Photos
© 2026 Oy Market Touch Ltd. · Market Touch Signal